Lagging behind other vaccine candidates, the U.S. government pulled the funding for a late-stage study testing Inovio’s COVID-19 vaccine candidate INO-4800, prompting the company to consider pursuing a trial largely outside the country.
The decision followed the U.S. Food and Drug Administration in September putting the Phase 3 portion of the mid-to-late stage trial on hold for more information on the device used to inject the shot.
The U.S. Department of Defense will continue to fund Inovio’s ongoing mid-stage study of INO-4800.
Earlier this month, Inovio received $6.9 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to work with the International Vaccine Institute on an early-to-mid-stage trial for INO-4800 in South Korea.
